This article is more than 5 years old. Information may no longer be current.

VIDEO: Second-line use of rituximab shows better retention rate than third-line use

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — At the American College of Rheumatology Annual Meeting, Denis Choquette, MD, FRCP(C), FMSQ, of the University of Montréal, spoke about the 6-year follow-up report from the Rhumadata Clinical Database and Registry, a study of the use of rituximab compared with anti-TNF agents as second- and third-line therapy in patients with rheumatoid arthritis.

He said second-line use showed better retention rates than third-line use and results of the study indicate that using rituximab as a second agent after failing a first anti-TNF agent could be a better strategy than waiting to use it after two different anti-TNF failures.